Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Genaissance Pharm. Inc. (NasdaqNM:GNSC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 28Price hit new 52-week low ($4.51)
Location
Five Science Park
New Haven, CT 06511
Phone: (203) 773-1450
Fax: (203) 562-9377
Email: contact-us@genaissance.com
Employees (last reported count): 172
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 43%
·Institutional: 35% (61% of float)
(61 institutions)
·Net Inst. Buying: 596.0K shares (+6.96%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Genaissance Pharmaceuticals Inc. develops technology for applying population genomics to improve the development, marketing and prescribing of drugs. The Company discovers genomic markers that can be used to predict which patients will respond effectively to a drug. The Company combines sophisticated informatics and proprietary procedures with DNA sequencing and genomic variation measurement capabilities to allow pharmaceutical companies to integrate population genomics into the development, marketing and prescribing of new and existing medicines. The Company has invested considerable resources in constructing a production process to discover genomic variation with the goal of discovering the range of genomic variation among all of the pharmaceutically relevant genes. The Company calls this complete solution its HAP Technology.
More from Market Guide: Expanded Business Description

Financial Summary
GNSC develops technology for applying population genomics and informatics to improve the development, marketing and prescribing of drugs. For the six months ended 6/30/01, revenues totaled $2.1 million, up from $120 thousand. Net loss applicable to Common decreased 65% to $24.4 million. Revenues reflect higher license revenues due to the commercialization of the Company's HAP program. Lower loss also reflects the absence of a $50.2 million beneficial conversion and dividend.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Jurgen Drews, M.D., 67
Chairman
--  --  
Gualberto Ruano, M.D, Ph.D., 41
CEO, Director
$930K--  
Kevin Rakin, 40
Pres, CFO, Director
581K--  
Kenneth Kashkin, M.D., 50
Exec. VP and CMO
131K--  
Gerald Vovis, Ph.D., 58
Sr. VP, CTO
223K$95K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:GNSCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 28-Aug-2001
$4.51 
Recent Price$5.59 
52-Week High
on 8-Nov-2000
$34.50 
Daily Volume (3-month avg)93.7K
Daily Volume (10-day avg)210.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-74.9%
52-Week Change
relative to S&P500
-66.3%
Share-Related Items
Market Capitalization$127.0M
Shares Outstanding22.7M
Float13.0M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.60 
Earnings (ttm)-$2.31 
Earnings (mrq)-$0.58 
Sales (ttm)$0.13 
Cash (mrq)$3.61 
Valuation Ratios
Price/Book (mrq)1.55 
Price/EarningsN/A 
Price/Sales (ttm)43.21 
Income Statements
Sales (ttm)$2.70M
EBITDA (ttm)-$48.2M
Income available to common (ttm)-$47.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-37.66%
Return on Equity (ttm)-63.41%
Financial Strength
Current Ratio (mrq)6.85 
Debt/Equity (mrq)0.30 
Total Cash (mrq)$82.1M
Short Interest
As of 8-Aug-2001
Shares Short552.0K
Percent of Float4.2%
Shares Short
(Prior Month)
637.0K
Short Ratio7.17 
Daily Volume77.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.